131 research outputs found
Human Embryonic Stem Cell Technology: Large Scale Cell Amplification and Differentiation
Embryonic stem cells (ESC) hold the promise of overcoming many diseases as potential sources of, for example, dopaminergic neural cells for Parkinson’s Disease to pancreatic islets to relieve diabetic patients of their daily insulin injections. While an embryo has the innate capacity to develop fully functional differentiated tissues; biologists are finding that it is much more complex to derive singular, pure populations of primary cells from the highly versatile ESC from this embryonic parent. Thus, a substantial investment in developing the technologies to expand and differentiate these cells is required in the next decade to move this promise into reality. In this review we document the current standard assays for characterising human ESC (hESC), the status of ‘defined’ feeder-free culture conditions for undifferentiated hESC growth, examine the quality controls that will be required to be established for monitoring their growth, review current methods for expansion and differentiation, and speculate on the possible routes of scaling up the differentiation of hESC to therapeutic quantities
Transfer of passive immunity and serum proteinogram in the first six months of life of Criollo Lageano and black and white holstein calves
An improved approach to medical data sets classification: artificial immune recognition system with fuzzy resource allocation mechanism
Plasma Unconjugated and conjugated 17-hydroxycorticosteroids in different clinical disorders
INTERACTION BETWEEN SECRETION OF THE GONADOTROPHINS, PROLACTIN, GROWTH HORMONE, THYROTROPHIN AND CORTICOSTEROIDS IN MAN: THE EFFECTS OF LH/FSH-RH, TRH AND HYPOGLYCAEMIA ALONE AND IN COMBINATION
GABA and Muscimol Inhibit the Release of Prolactin from Dispersed Rat Anterior Pituitary Cells
Recommended from our members
Effect of Prolactin on In Vitro Expression of the Bovine Mammary Immunoglobulin G1 Receptor
Explants of mammary tissue from cows in late pregnancy were incubated for 72h in serum-free, hormonally defined media to investigate the regulation of the bovine mammary IgG1 receptor. Treatments included incubation in basal medium alone, basal medium plus estradiol-17β, basal medium plus prolactin, or basal medium plus estradiol-17β and prolactin. α-Lactalbumin production was measured by radioimmunoassay in culture supernatants collected at 24, 48, and 72h. Explants were examined immunohistochemically for expression of the IgG1 receptor at 24, 48, and 72h. α-Lactalbumin concentrations increased, and IgG1 receptor expression decreased, by 72h with explants cultured in the medium containing prolactin. Results suggest that, in addition to its positive lactogenic effect, prolactin decreases expression of the bovine mammary IgG1 receptor
Recommended from our members
Expression of Immunoglobulin G1 Receptors by Bovine Mammary Epithelial Cells and Mammary Leukocytes
The objective of this study was to identify and evaluate expression of IgG1 receptors by different cell types in mammary tissue sections and digest-dispersed cells from the bovine mammary gland. An immunohistochemical system utilizing avidin-biotin-peroxidase complex demonstrated epithelial expression of IgG1 receptors in mammary tissue sections from cows producing colostrum but not from cows in lactation. Fluorescence flow cytometry demonstrated that cells dispersed in digests from both tissues producing colostrum and lactating tissues selectively bound IgG1. Fluorescence flow cytometry, using monoclonal antibodies to cell surface molecules, cytokeratin, and IgG1 revealed that leukocytes constituted the largest percentage of cells and were the predominant cell type binding IgG1 in mammary tissue digests. Although IgG1 binding to epithelial cells predominated in the gland during colostrum production in situ, digestion and filtration to produce single cell suspensions resulted in the loss of large numbers of epithelial cells. Studies of Ig binding of cells produced by enzymatic digestion must account for the types of cells surviving the digestion process
The effect of growth hormone replacement therapy on adrenal androgen secretion in adult onset hypopituitarism
OBJECTIVE: Growth hormone replacement therapy in GH-deficient children is associated with enhanced adrenal androgen production, raising the possibility that GH might stimulate adrenocortical hormone secretion. This has not been extensively investigated in adults to date. GH is a potent modulator of the activity of the 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) enzyme and by altering cortisol metabolism can affect the function of the hypothalamo-pituitary-adrenal (HPA) axis and therefore potentially of adrenal androgen secretion. This study examined the effects of GH replacement in GH-deficient adults on adrenal androgen secretion. DESIGN: Prospective study of the effect of GH replacement therapy on adrenal androgen production in patients with adult onset hypopituitarism over a 12-month period. PATIENTS AND METHODS: Thirty adult GH-deficient patients were classified into two groups according to their cortisol responses to an insulin-induced hypoglycaemia or a glucagon stimulation test: 13 patients were adrenocorticotropic hormone (ACTH)-sufficient (nine females, age 45.1 +/- 3 years), whereas 17 patients were ACTH-deficient (11 females, age 45.5 +/- 3 years). Serum samples were collected before patients were initiated on GH replacement therapy using a dose titration regimen, and after 6 and 12 months on GH therapy for measurement of serum IGF-I, dehydroepiand-rosterone sulphate (DHEAS), Delta4-Androstenedione (A4), testosterone, cortisol, sex hormone binding globulin (SHBG) and cortisol binding globulin (CBG). RESULTS: Six months after the initiation of GH replacement therapy, serum IGF-I levels were within the normal age-related reference range in both groups of patients and this was maintained at 12 months [in all patients 0 vs. 6 months: median (interquartile range): 92.5 ng/ml (73-116 ng/ml) vs. 191 ng/ml (159-224 ng/ml), P < 0.01]. In both ACTH-sufficient and -deficient groups of GH-deficient patients, pretreatment serum DHEAS levels were lower than the normal age-related reference range (P < 0.01); the ACTH-deficient patients had significantly lower DHEAS levels than the ACTH-sufficient patients [median (interquartile range): 0.5 micro mol/l (0.4-1.2 micro mol/l) vs. 1.5 micro mol/l (0.6-2.7 micro mol/l), P < 0.05]. Following GH replacement therapy, median levels of serum DHEAS levels rose from 1.5 micro mol/l (0.6-2.7 micro mol/l) to 1.9 micro mol/l (1.9-3.9 micro mol/l) in ACTH-sufficient patients, increasing in 11 of the 13 patients (P < 0.02). In this group, the median percentage increase from baseline was 32% at 6 months (P < 0.05). In contrast, baseline serum DHEAS levels [0.5 micro mol/l (0.4-1.2 micro mol/l)] declined in or from the measurable range in 47% of ACTH-deficient patients [median -16%; range -36-0] and only in one patient a + 0.2 micro mol/l increase was observed. GH dose requirements tended to be lower in ACTH-sufficient patients [1.2 U/day (0.8-1.4 U/day) vs. 1.6 U/day (1.0-2.0 U/day); P = 0.062]. There were no significant changes in serum testosterone, A4, SHBG and/or CBG levels, compared to the pretreatment levels, in either group of patients over the 12 months of GH replacement. CONCLUSIONS: This study shows that median serum DHEAS levels are significantly lower in GH-deficient patients, even those with intact ACTH reserve, than in aged-matched controls. GH replacement therapy is associated with a significant increase in mean serum DHEAS only in ACTH-sufficient patients. These findings are consistent with either (i) GH stimulation of adrenal androgen production in the permissive presence of ACTH or (ii) an inhibitory effect of GH on 11beta-HSD type 1 activity leading to enhanced cortisol clearance, subsequent activation of the HPA axis and ACTH-mediated androgen secretion
- …